TITLE

Makena

PUB. DATE
March 2011
SOURCE
Pharmaceutical Representative;Mar2011, Vol. 41 Issue 3, p11
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the decision of the U.S. Food & Drug Administration (FDA) to approve Makena injection to reduce the risk of preterm delivery before 37 weeks of pregnancy.
ACCESSION #
59218730

 

Related Articles

  • FDA actions.  // Primary Care Reports;Feb2013 Pharmacology Watch, p2 

    The article reports on the approval of the pasireotide diaspartate injection marketed by Novartis AG as Signifor by the U.S. Food and Drug Administration (FDA) for the treatment of Cushing's disease in patients who are not in line for surgery and for those patients whose surgery has not worked.

  • New molecular entities.  // Formulary;Jul2005, Vol. 40 Issue 7, p210 

    Provides information on drugs that were approved by the United States Food and Drug Administration. Exenatide injection; Tigecycline antibiotic; Tipranavir.

  • FDA actions in brief.  // Formulary;Dec2008, Vol. 43 Issue 12, p434 

    The article focuses on the approval of drugs by the U.S. Food and Drug Administration (FDA). Muscairinillc receptor antagonist has been approved for the treatment of overactive bladder. Fesoterodine is a muscarinic receptor antagonist which produces its effects by inhibiting the receptors that...

  • FDA approves kallikrein inhibitor to treat hereditary angioedema. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;1/15/2010, Vol. 67 Issue 2, p93 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the marketing of Dyax Corp.'s injection targeting kallikrein inhibitor for the treatment of hereditary angioedema. Ecallantide, a prime component of the injection, binds to plasma kallikrein and blocks its binding...

  • Once-a-month injection approved to treat three types of arthritis. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;6/1/2009, Vol. 66 Issue 11, p968 

    The article discusses the approval of the Simponi or golimunab injection by the U.S. Food & Drug Administration and Centocor Ortho Biotech Inc. The injection is a once-monthly treatment for three types of arthritis. The article lists the common side effects of the medication which may include...

  • Recently Approved.  // Pharmaceutical Representative;Jul2008, Vol. 13 Issue 7, p14 

    The article reports on the newly approved drugs by the U.S. Food and Drug Administration (FDA). The FDA approved Otsuka America Pharmaceutical's Abilify as an adjunctive therapy for manic and mixed episodes related with bipolar I disorder, with or without psychotic features in adults. The Advair...

  • RECENT APPROVALS.  // Pharmaceutical Processing;Jan2009, Vol. 24 Issue 1, p30 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the injectable drug, degarelix for prostate cancer in 2009. Degarelix, which belongs to a class of agents called gonadotropin releasing hormone (GnRH) receptor inhibitors, is intended to treat patients with...

  • FDA actions. Elliott, William T. // Critical Care Alert;Feb2013 Pharmacology Watch, p2 

    The article discusses the approval of pasireotide diaspartate injection for the treatment of Cushing's disease by FDA. It presents safety, efficacy and side effects of the drug.

  • FDA actions. Elliott, William T. // Infectious Disease Alert;Feb2013 Pharmacology Watch, p2 

    The article reports on the approval of pasireotide diaspartate injection by the U.S. Food and Drug Administration (FDA) for the treatment of Cushing's disease in patients who are not candidates for surgery or for whom surgery has not worked.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics